Revolutions Medical Corporation
Revolutions Medical — Investor Presentation (2011)
11 slides from Revolutions Medical's investor presentation, Apr 9, 2011
Slide 1: Revolutions Medical Report 2011
Revolutions Medical Report 2011 Charleston, South Carolina
Slide 2: Our Mission
Our Mission: Revolutions Medical Corporation, Inc. (Company) is committed to developing and distributing new products and tools for the medical industry, whether internally or through acquisitions. Our goal is to make healthcare safer and less expensive by reducing risks, time and expense. Currently
Slide 3: Rondald Wheet
Rondald Wheet CEO, Chairman of the Board Mr. (Ron) Wheet is the CEO and Chairman of the Board of Revolutions Medical Corporation. Since 2005 his unwavering leadership has achieved the Company’s first FDA 510K Clearance on its proprietary RevVacTM Safety Syringe, and he is positioning the Company for
Slide 4: Thomas O'Brien
Thomas O’Brien President, Director Mr. (Thomas) O’Brien has more than twenty-five (25) years of general management experience in the medical device industry. He has special expertise in domestic and international sales, and marketing and distribution of high technology medical systems and services.
Slide 5: Safety Syringe Market Overview
Safety Syringe Market Overview More than 1.3 million people die each year from unsafe injection practices, according to the World Health Organization. Potential routes of transmission of blood borne pathogens such as HIV and Hepatitis C include needlestick injuries and the reuse, sharing, or unsafe
Slide 6: Prefill Market Overview
to activate the safety mechanism before the needle is removed from Currently, pharmaceutical companies must purchase safety devices sep- the patient, rather than those that retract the needle after it is removed arately and attach them to a standard prefilled syringe after the com- from the patient,
Slide 7: Market Segmentation and Growing Product Opportunity; Rollout and Early Break-even Strategy
Market Segmentation and Rollout and Growing Product Opportunity Early Break-even Strategy Approximately 7B safety syringes were sold worldwide last year. Over With our production of 1ml and 3ml safety syringes on schedule for Q2 200M auto-retractable safety syringes were priced at 20% to 30% 2011 an
Slide 8: Reported Needlestick Injuries in Massachusetts Healthcare Facilities
Reported Needlestick Injuries in Massachusetts Healthcare Facilities Safety vs. Standard (Non-Safety) Syringes “Hospitals that have adopted safety devices in all situations... and still experience needlestick injuries often see the injuries oc- cur as a result of non-activation of the device. So com
Slide 9: Clinical Applications and Validation of Its MRI Software Tools
Revolutions Medical Corporation Begins Clinical Applications and Validation of Its MRI Software Tools Studies utilizing RevMed proprietary MRI tools are now Segmentation Using Fuzzy C‐Means Clustering’ is built on underway. The studies are being led by H. Keith Brown, an extensive body of work incor
Slide 10: Financial Projections and Market Comparison
Financial Projections (*) 2011E(1) 2012E 2013E 2014E Sales $ $12M $29M $55M $100M Sales Units 36M 72M 170M 350M Gross Margin % 48% 48% 48% 48% Operating Income $350K $7.5M $15M $28M (1) Assumptions for 2011 (a) 1ml and 3ml Fixed Needle syringes production commencing Q2 2011 (b) 5ml/10ml Fixed Needle
Slide 11: Revolutions Medical Corporation Contact
Contact Revolutions Medical Corporation 670 Marina Drive, 3rd Floor Charleston, SC 29492 Sarah E. Kavalla, Corporate Office Manager Email: Skavalla@revolutionsmedical.com Ron Wheet, CEO/Chairman of the Board Email: Rwheet@revolutionsmedical.com 843-971-4848 Office | 843-971-6917 Fax